A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)
An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Sponsor: Astellas Pharma Global Development, Inc.
Terminated
Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies
Other terminated trials from Astellas Pharma Global Development, Inc.
- Carcinoma Transitional Cell · Phase PHASE1 · Sep 2025
- Solid Tumor · Phase PHASE1 · Sep 2025
- Acute Myeloid Leukemia (AML) · Phase PHASE1/PHASE2 · Mar 2025
- B-cell Lymphoma · Phase PHASE1 · Dec 2024
- Advanced Solid Tumors · Phase PHASE1 · Oct 2024
More terminations from Astellas Pharma Global Development, Inc.
Other Non-small Cell Lung Cancer (NSCLC) trials with similar outcome
Listed as NCT02588261, this PHASE3 trial focuses on Non-small Cell Lung Cancer (NSCLC) and remains terminated or withdrawn. Sponsored by Astellas Pharma Global Development, Inc., it has been updated 16 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE3
-
Jan 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
▶ Show 11 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Terminated PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Global Development, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Albuquerque, United States , Alkmaar, Netherlands , Amadora, Portugal , Arkhangelsk, Russia , Arnhem, Netherlands , Atlanta, United States , Aventura, United States , Aviano, Italy , Bangkok, Thailand and 131 more locations